AR SB192

Finds that increasing access to biosimilar medical products can significantly reduce prescription drug costs and are approved by the FDA to the same standards as reference medications

Establishes legislative intent to eliminate barriers to biosimilar medical products and promote their cost savings to Arkansas consumers

Amends Arkansas Code § 23-79-2104(h) to allow healthcare insurers, health benefit plans, and utilization review organizations to require patients to try generic equivalents, interchangeable biological products, or biosimilar medical products only if the requirement meets step therapy protocol exception standards

Preserves the ability of pharmacists to effect prescription drug substitutions consistent with § 17-92-503

Preserves the ability of healthcare providers to prescribe prescription drugs determined to be medically necessary